Evidence map›Paper›PMID 21423876›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2010

Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice.

Kristen Underhill, Don Operario, Margie Skeer, Matthew Mimiaga, Ken Mayer

Registry-linked trialAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02611362 (A Multilevel Gaming Intervention for Persons on PrEP), which is not on this map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02611362 nacompletednot on this mapstarted 2015, after this paper: background citation

A Multilevel Gaming Intervention for Persons on PrEP

TypeinterventionalSponsorRhode Island HospitalRan2015 to 2019Enrolled82ConditionsMSM, PrEP, HIV RiskArmsIMB Gaming Intervention
3 · Its place in the literature

Who cites it

56 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Utilizing emergency departments for pre-exposure prophylaxis (PrEP).Journal of the American College of Emergency Physicians open · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kristen UnderhillDepartment of Community Health, Brown University.
Don Operario
Margie Skeer
Matthew Mimiaga
Ken Mayer

Funding

Virology CoreP01AA019072 · NIAAA · BROWN UNIVERSITY · PI WRAY, TYLER BLAKE · 2010 to 2024
$19.7M
ALCOHOL INTERVENTION/TREATMENT OUTCOME RESEARCH TRAININGT32AA007459 · NIAAA · BROWN UNIVERSITY · PI ROBERT MIRANDA, PETER M. MONTI · 1986 to 2026
$13.3M
NIAAA NIH HHS P01 AA019072NIAAA NIH HHS T32 AA007459
6 · The paper itself

Abstract

Antiretroviral pre-exposure prophylaxis (PrEP) drugs may be partially effective for preventing HIV transmission. In anticipation of clinical trial results, behavioral HIV prevention scientists have begun examining possible challenges in the implementation of PrEP in clinical practice or community settings. These efforts have acknowledged the need to supplement PrEP drug delivery with risk-reduction counseling and ongoing HIV testing, and we suggest that an even wider range of clinical, diagnostic, behavioral, and monitoring services will be necessary to support PrEP as a population-level HIV prevention strategy. This Commentary offers an integrated structure for optimizing PrEP delivery in clinical practice, which includes five components: 1) PrEP drugs; 2) safety screening and repeated HIV testing; 3) behavioral interventions to facilitate PrEP initiation, maintain adherence, and minimize risk compensation; 4) the development of strategies to engage PrEP users and the healthcare system over the long term; and 5) population-level monitoring. We provide a brief overview of each component and highlight implications of this five-part package for implementation. Attempts to plan for scale-up without explicitly addressing non-pharmaceutical elements may overlook critical implementation needs, barriers, and facilitators.

Identifiers

PMID21423876
PMCPMC3058525

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.